
About VAROLIS GmbH
Honeybees are essential for food production, resilient agriculture, and our ecosystem. At the same time, the parasitic Varroa mite threatens our honeybees. By now, every colony is infested, and without treatment, colonies collapse within 2 years. Options for protecting bees from Varroa mites are limited, unreliable, and outdated. VAROLIS is committed to obtaining regulatory approval for our novel active ingredient, LIMITEX, as a veterinary product. LIMITEX is highly efficient and easy to use. It is well tolerated by bees and leaves no residues in bee products. The data have been tested and validated multiple times in field trials under beekeeping conditions. VAROLIS has freedom to operate and licenses for all necessary patents. The market size exceeds 2 billion euros annually, production costs are low, and the product is highly profitable. Based on conservative assumptions, VAROLIS will achieve return on investment just 2 years after market launch. Our preclinical data package and preliminary work on quality and safety for LIMITEX reduce the risk in the approval process. Our team has experience as entrepreneurs, scientists, beekeepers, and in drug development. Additionally, we are supported by a broad team of consultants and experts. Beyond the positive impact on our environment, our B2B and B2C business model opens economically promising opportunities. To achieve our goal, we now need financial support from strategic partners who want to accompany us on our path toward improved bee protection, resilient agriculture, food security, biodiversity, and healthy ecosystems.
